David Hallal

David Hallal has served as Chief Executive Officer of Scholar Rock since April 2025. He has served as Chairman of Scholar Rock’s Board of Directors since July 2017. Under David’s leadership, Scholar Rock has raised more than $1 billion and successfully advanced a highly innovative new therapy, apitegromab, for children and adults with spinal muscular atrophy, through positive Phase 3 studies and is now awaiting approval in the US and Europe in 2026.

Previously, he served as Chairman and Chief Executive Officer of ElevateBio, a genetic medicines company generating >$100M in revenues by providing advanced technologies and manufacturing platforms to many biopharmaceutical companies. David continues to serve as Executive Chairman at ElevateBio, which remains the leading advanced therapies tech and service provider through a disruptive foundry business model.

Prior to Scholar Rock and ElevateBio, from 2006-2016, David spent more than a decade at Alexion Pharmaceuticals where he served as Chief Executive Officer, Chief Operating Officer, and Chief Commercial Officer and played a central role in transforming the company from the pre-commercial stage to greater than $3 billion in annual revenues with operations in more than 50 countries around the world. As the CEO of Alexion, as an S&P 500 company, David transitioned the company from a single product to a multi-product enterprise with multiple billion-dollar rare disease therapies for children and adults living with severe disorders, which eventually led to a $39 billion acquisition by Astra Zeneca.

Prior to Alexion, from 1988-2006, David held commercial leadership positions at biopharmaceutical companies where he launched and expanded the adoption of numerous first-in-class and blockbuster products at Eyetech, Biogen, Amgen, and The Upjohn Company.

He also serves as the Chairman of the Board of Directors of Kalaris. David holds a BA in psychology from the University of New Hampshire and today serves on the UNH Foundation Board of Directors.